Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Abnormal Proliferation02:23

Abnormal Proliferation

5.4K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Mismatch Repair01:20

Mismatch Repair

7.1K
Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
7.1K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

3.9K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
3.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

CD52 and OXPHOS-potential targets in ibrutinib-treated mantle cell lymphoma.

Cell death discovery·2022
Same author

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial.

HemaSphere·2022
Same author

MYC multimers shield stalled replication forks from RNA polymerase.

Nature·2022
Same author

Panel Sequencing of Primary Cutaneous B-Cell Lymphoma.

Cancers·2022
Same author

Vitamin D Receptor Expression Is Significantly Decreased in Bone Metastases Compared to Matched Primary Breast Cancer Tumours.

Cancer investigation·2022
Same author

Identification of Disparities in Personalized Cancer Care-A Joint Approach of the German WERA Consortium.

Cancers·2022

相关实验视频

Updated: Apr 13, 2026

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection
10:39

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection

Published on: November 27, 2014

8.6K

在人类淋巴瘤中发生瘤活性MYD88突变.

Vu N Ngo1, Ryan M Young, Roland Schmitz

  • 1Metabolism Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

Nature
|December 24, 2010
PubMed
概括

活化B细胞样DLBCL的存活率取决于MYD88适应蛋白突变. 这些致癌MYD88突变,特别是L265P,通过激活关键信号通路来驱动淋巴瘤细胞生长,提供新的治疗点.

更多相关视频

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.7K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

2.0K

相关实验视频

Last Updated: Apr 13, 2026

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection
10:39

In Vitro Analysis of Myd88-mediated Cellular Immune Response to West Nile Virus Mutant Strain Infection

Published on: November 27, 2014

8.6K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

9.7K
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

2.0K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 免疫学 免疫学 免疫学

背景情况:

  • 激活型B细胞样 (ABC) 扩散型大B细胞淋巴瘤 (DLBCL) 是一个具有挑战性的亚型,治疗选择有限.
  • 构成性核因子 (NF) -κB和JAK激酶信号通路对于ABC DLBCL细胞生存至关重要.
  • 这种异常信号传递的精确遗传基础仍然不完全理解.

研究的目的:

  • 为了研究MYD88适配蛋白在ABC DLBCL病变发生中的作用.
  • 在ABC DLBCL瘤中识别和描述MYD88中的瘤突变.
  • 阐明MYD88突变对信号通路和细胞存活的功能影响.

主要方法:

  • 查RNA干扰以评估MYD88,IRAK1和IRAK4对于ABC DLBCL存活的关键性.
  • 高通量RNA重序测用于识别MYD88.8.中的突变.
  • 功能性测试评估MYD88突变对蛋白质复合体组合,激酶活性和下游信号传导的影响.

主要成果:

  • MYD88和相关酶IRAK1/IRAK4对于ABC DLBCL细胞生存至关重要.
  • 在ABC DLBCL中发现了MYD88 Toll/IL-1受体 (TIR) 域中经常出现的瘤原性突变.
  • 在29%的ABC DLBCL瘤中发现了MYD88中的L265P替代,并作为功能获取突变,促进构成信号和细胞存活.
  • 在其他淋巴瘤亚型中也观察到MYD88突变,包括粘膜相关的淋巴组织淋巴瘤.

结论:

  • MYD88信号通路是ABC DLBCL病原体的组成部分.
  • 获得功能MYD88突变,像L265P一样,通过激活NF-κB和JAK/STAT3通路来驱动瘤发生.
  • 针对IRAK4激酶和MYD88通路的其他组件,为MYD88突变DLBCL提供了一个有前途的治疗策略.